Skip to content

Using Stem Cells to Model Psychiatric Disorders: NIH Grantees Meeting » Meeting Agenda

Bethesda, Maryland

October 26, 2010
Time Event
8:00 a.m.

Arrival and refreshments

8:30 a.m.

Welcome, Overview of Meeting Goals

Thomas Insel, M.D.

David Panchision, Ph.D.
Introduction and Overview of Meeting Goals

8:50 a.m.

Patient Selection Criteria: First steps in reverse translation (diagnostic classification; genetic heterogeneity and overlap among diseases; rare mutations of major effect; choice of processes to study)

Russell Margolis, M.D.
Schizophrenia and bipolar disorder

Joachim Hallmayer, M.D.
Autism spectrum disorders


9:30 a.m.

iPSC derivation and validation strategies

(induction by viral, episomal, protein, small molecules; standards for validating self-renewal and pluripotency, genomic stability)

James Ellis, Ph.D.
Retroviral reprogramming methods and pluripotency criteria

Paul Tesar, Ph.D.
Integration-free reprogramming methods

Kwang-Soo Kim, Ph.D.
Protein-based reprogramming methods

Jeanne Loring, Ph.D.
Molecular diagnostics for pluripotency


10:50 a.m. Break
11:10 a.m.

Assays with relevance to disease: Autism, Rett, Fragile X (genetics, in vitro / in vivo differentiation, functional assays, phenomic analysis, high throughput screens, rescue of defects, comparison with mouse models)

Ricardo Dolmetsch, Ph.D.
Mouse-human comparisons of gene variants associated with autism

Flora Vaccarino, M.D.
Neuronal differentiation from human iPSCs

Shelley Halpain, Ph.D.
Morphology based assays of rodent and human iPSCs (Rett)

Yi Sun, Ph.D.
Assaying Mecp2 deficient human ESCs

Philip Schwartz, Ph.D.
In vivo and in vitro diagnosis of FMR1 gene mutations


12:40 p.m. Break and working lunch
1:00 p.m.

Assays with relevance to disease: Schizophrenia and Bipolar Disorder

Li-Huei Tsai, Ph.D.
Analysis of DISC1 variants in iPSCs from schizophrenia and bipolar disorder patients

Hongjun Song, Ph.D.
Analysis of DISC1 in mouse and a human cohort

Maria Karayiorgou, M.D.
Generation of cellular models of psychiatric disorders from patients carrying pathogenic CNVs

Herbert Lachman, M.D.
Analysis of glutamatergic neurons using iPSCs derived from patients with schizophrenia

Lorenz Studer, M.D.
Tools for purification of heterogeneous cell types relevant to schizophrenia

Stephen Haggarty, Ph.D.
High throughput assays for studying bipolar disorder

Ilyas Singec, M.D.
Scalable, efficient, rapid, and uniform neural induction of human pluripotent cells for high-throughput drug screening, and comprehensive proteomic profiling of neuropsychiatric disorders


3:20 p.m.


3:40 p.m

Resources, Sharing, and Roadblocks (MTAs, cell banking and patient confidentiality; data sharing formats and common data elements; intellectual property & resource sharing; technological hurdles)

Philip Schwartz, Ph.D.
Cell banks for iPSC research

Michael Huerta, Ph.D.
Serving up stem cell data

Andrea Baruchin, Ph.D.
Public-Private Partnerships

4:20 p.m. Future Priorities, Plans for Moving Forward (novel biomarkers and targets relevant to mental illnesses; pharmacogenetics, candidate drug and toxicology screening; scaling to high-throughput; how to facilitate basic to translational to clinical application in psychiatric disorders)
5:00 p.m. Departure